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The MYC oncogene contributes to the genesis of many human cancers. Recent insights into its
expression and function have led to therapeutic opportunities. MYC’s activation by bromodomain
proteins could be inhibited by drug-like molecules, resulting in tumor inhibition in vivo. Tumor
growth can also be curbed by pharmacologically uncoupling bioenergetic pathways involving
glucose or glutamine metabolism from Myc-induced cellular biomass accumulation. Other
approaches to halt Myc on the path to cancer involve targeting Myc-Max dimerization or
Myc-induced microRNA expression. Here the richness of our understanding of MYC is reviewed,
highlighting new biological insights and opportunities for cancer therapies.Introduction
MYC belongs to a family that includesMYCL (L-Myc) andMYCN
(N-Myc) (Brodeur et al., 1984; Kohl et al., 1984; Maris, 2010; Nau
et al., 1985). Whereas the role of L-Myc is less well understood,
N-Myc expression is tissue restricted, and N-Myc can substitute
for c-Myc in murine development (Malynn et al., 2000). The
protooncogene MYC lies at the crossroads of many growth-
promoting signal transduction pathways and is an immediate
early response gene downstream of many ligand-membrane
receptor complexes (Armelin et al., 1984; Kelly et al., 1983)
(Figure 1A). MYC expression is highly regulated, such that its
level of expression is tightly control by a number of mechanisms
involving many transcriptional regulatory motifs found within its
proximal promoter region (Brooks and Hurley, 2010; Hurley
et al., 2006; Levens, 2010).
The road to MYC’s discovery was paved by early studies of
fulminant chicken tumors caused by oncogenic retroviruses,
leading to the identification of the v-myc oncogene that causes
myelocytomatosis (leukemia and sarcoma) (Duesberg and
Vogt, 1979; Hu et al., 1979; Sheiness and Bishop, 1979). The
v-myc oncogene was co-opted from the host cellular genome
containing the protooncogenic version or c-myc (Vennstrom
et al., 1982). Although the search for comparable human retrovi-
ruses failed to recapitulate the retroviral oncogene paradigm in
human cancers, the discovery that human MYC is consistently
altered by balanced chromosomal translocation in Burkitt
lymphoma marked it as a bona fide human oncogene (Dalla-
Favera et al., 1982; Taub et al., 1982).MYC is frequently translo-
cated in multiple myeloma (Shou et al., 2000) and is one of the
most highly amplified oncogenes among many different human
cancers (Beroukhim et al., 2010). Defects in the Wnt-APC
pathway found in human colon carcinoma result in enhanced
TCF transcriptional activation of MYC (He et al., 1998). MYC is
downstream of deregulated Notch signaling pathways found in
T cell leukemia (Palomero et al., 2006; Sharma et al., 2006;
Weng et al., 2006). Hence, alterations of MYC are commonly
found on the path to cancer.22 Cell 149, March 30, 2012 ª2012 Elsevier Inc.In addition to its role in tumorigenesis,MYCwas also identified
as one of four genes, including Sox2, Oct4, and KLF4, that could
collectively reprogram fibroblasts to a pluripotent stem cell state
(Laurenti et al., 2009; Singh and Dalton, 2009; Takahashi and
Yamanaka, 2006). Given its pivotal role in cell growth, prolifera-
tion, tumorigenesis, and stem cells, it appears timely to review
what is currently understood about MYC by addressing the
following key questions. What are the molecular functions of
its protein product, Myc? How does MYC contribute to tumori-
genesis? What are the differences between theMYC protoonco-
gene and its deregulated form found in a variety of human
cancers? Could MYC or Myc’s target genes be targeted for
cancer therapy?
Myc, Checkpoints, and Neoplastic Transformation
Early in vitro studies of MYC revealed its potential to transform
normal embryonic fibroblasts in cooperation with other
oncogenes (Land et al., 1983). These studies set the stage for
transgenic mouse studies that provided the evidence that
deregulated expression of MYC is sufficient to drive tumorigen-
esis in a number of transgenicmouse tissues (Adams et al., 1985;
Chesi et al., 2008; Leder et al., 1986). Retroviral insertional muta-
genesis further identified c-Myc as a major murine oncogene
(Akagi et al., 2004). In each of these models, however, additional
mutagenic events are necessary for tumor formation as evi-
denced by a predictable time delay before the onset of tumors
(Beer et al., 2004; Ellwood-Yen et al., 2003; Felsher and Bishop,
1999a; Pelengaris et al., 1999). Hence, MYC requires other
genetic alterations in vivo to enable its tumorigenic potential.
Mammary carcinomas triggered by transgenic Myc expression
acquire K-ras mutations that render tumors aggressive (D’Cruz
et al., 2001). Acute overexpression ofMyc in normal cells triggers
checkpoints including ARF or p53 (Figure 1B), such that many
MYC-induced transgenic lymphomas lack functional Arf or p53
(Eischen et al., 1999; Zindy et al., 1998). The findings from trans-
genic mouse studies underscore a causal role forMYC in murine
cancers and support its tumorigenic role in human cancers.
Figure 1. Myc Regulates Cell Growth and Proliferation
(A) The MYC protooncogene is depicted downstream of receptor signal
transduction pathways, which elicit positive or negative regulation of theMYC
gene. MYC produces the transcription factor Myc, which dimerizes with
Max and binds target DNA sequences or E boxes (with the sequence 50-
CANNTG-30) to regulate transcription of genes involved in cell growth and
proliferation. The WNT pathway is depicted with APC negatively regulating
b-catenin, which upon nuclear translocation participates in the transactivation
of MYC, such that loss of APC results in constitutive oncogenic MYC
expression.
(B) When MYC is deregulated, by gene amplication, chromosomal trans-
location, or loss of upstream regulators, such as APC, acute sustained
oncogenicMYC expression results in checkpoint activation of p53 or Arf. Loss
of checkpoint regulation through mutations of p53 or Arf, for example,
uncloaks MYC’s full tumorigenic potential.MYC is documented to play a role in tumor initiation; however,
whether it also participates in tumor maintenance had previously
been unclear. Knockdown of MYC in established cancer cell
lines in vitro appears to uniformly reduce cell proliferation and
in some instances induce apoptosis (Cappellen et al., 2007;
Koh et al., 2011a; Wang et al., 2008). In transgenic mouse
models with inducible MYC, established tumors regress upon
withdrawal of MYC ectopic expression, indicating that it plays
a role in tumor maintenance, and once established these tumors
are addicted to MYC (Arvanitis and Felsher, 2006). In fact,
expression of a dominant-negative inhibitor of Myc heterodime-
rization in vivo has resulted in tumor regression, suggesting thatinhibiting Myc function could be a feasible therapeutic strategy
(Soucek et al., 2008).
Molecular Functions of Myc
TheMYCmRNA generates Myc polypeptides, including one that
initiates at a CUG upstream of the canonical AUG start codon
and another that starts at an internal AUG (Blackwood et al.,
1994). The Myc protein translated from the canonical AUG
contains an N-terminal transcriptional regulatory domain fol-
lowed by a nuclear localization signal and a C-terminal region
with a basic DNA-binding domain tethered to a helix-loop-
helix-leucine zipper (HLH-Zip) dimerization motif. Myc dimerizes
with Max to bind DNA and mediates many of its functions (Amati
et al., 1992, 1993; Blackwood and Eisenman, 1991; Grinberg
et al., 2004; Kato et al., 1992; Kretzner et al., 1992). A distinct
function for the longer Myc polypeptide initiated at the upstream
CUG is not known (Blackwood et al., 1994; Hann et al., 1992), but
the shorter one initiated from an internal AUG appears to play
a role in stress response and perhaps serves as a dominant-
negative Myc protein (Spotts et al., 1997; Xiao et al., 1998).
Myc biology is further complicated by the finding that a cyto-
plasmic cleavage product of Myc (Myc-nick), which lacks the
nuclear localization signal and DNA-binding domain, can pro-
mote alpha-tubulin acetylation by recruiting GCN5 and promote
cell differentiation in a nontranscriptional manner (Conacci-
Sorrell et al., 2010).
Myc also appears to recruit DNA replication licensing factors
to catalyze DNA replication, although whether its transcriptional
function at replication origins is part-and-parcel of its DNA
replication activity is not yet clear (Dominguez-Sola et al.,
2007). Myc also plays an important nontranscriptional role in
stimulating cap-dependent translation (Cole and Cowling,
2008; Cowling and Cole, 2007). Lastly, Myc appears to function
even in the absence of functional Max protein as documented in
PC12 cells and more recently in Drosophila (Hopewell and Ziff,
1995; Steiger et al., 2008). Whether Myc could homo-oligomer-
ize or hetero-oligomerize with other helix-loop-helix proteins to
regulate transcription in the absence of Max in cells remains
unknown (Nair and Burley, 2003).
The Myc protein contains an unstructured N-terminal tran-
scriptional regulatory domain, which contains conserved Myc
boxes I and II, followed by Myc boxes lll and IV and a nuclear
targeting sequence (Cowling et al., 2006; Dang and Lee, 1988;
Kato et al., 1990; Pineda-Lucena and Arrowsmith, 2001). The
C-terminal domain comprises a basic HLH-Zip domain, which
is largely unstructured until it dimerizes with Max (Follis et al.,
2009; Hu et al., 2005; Mustata et al., 2009; Sauve´ et al.,
2007). The monomers assemble on DNA, and the heterodimer
locks onto and bends DNA through binding motifs (50-
CACGTG-30) termed E boxes (Park et al., 2004). The N-terminal
domain has been documented to form complexes with many
factors including TRRAP, GCN5, and TBP, which are likely to
induce more structured folding of the N-terminal Myc transcrip-
tional regulatory domain (Fladvad et al., 2005; Liu et al., 2003;
McEwan et al., 1996; McMahon et al., 2000; Nikiforov et al.,
2002). Hence, it is envisioned that when bound to DNA, the
Myc-Max heterodimer would recruit complexes that modify
chromatin (Figure 2).Cell 149, March 30, 2012 ª2012 Elsevier Inc. 23
Figure 3. The Myc miRNA Network
Myc regulates a network of miRNAs through activation of the miR-17-92
cluster and repression of dozens of miRs including Let-7, which was recently
shown to affect insulin signaling, miR-23a/b, which regulates glutaminase
expression, and miR-34a, which was shown to regulate lactate dehydroge-
nase (LDHA) expression. The miR-17 cluster contains miRNAs that target
PTEN, thereby activating AKT, and those that target proapoptotic BimL or
transcription factor E2F1 expression. miRNAs downstream of Myc have also
been implicated in EMT and angiogenesis.
Figure 2. Myc-Max-Mediated Transcription and Gene Repression
(A) The Myc-Max heterodimer is shown to interact with key cofactors, such as
transcription factor 2H (TFIIH) that triggers transcriptional elongation or
transformation/transcription domain-associated protein (TRRAP) that recruits
the GCN5, which acetylates histones, permitting transcription of target genes.
(B) Myc-Max also mediates gene repression. Miz-1 is shown tethered to the
initiator (INR) element to regulate transcription of target genes, which could be
silenced by Myc displacement of nucleophosmin (NPM), a Miz-1 cofactor, or
Myc induction of the ribosomal protein RPL23, which retains NPM in the
nucleolus, keeping it away from Miz-1.Although the mechanisms by which Myc activates transcrip-
tion, including the recruitment of histone acetylase, are
emerging, the mode by which Myc represses gene expression
is less well understood. Among the vast numbers of targets
that are repressed by Myc, a fraction is linked to Miz-1, which
activates these genes (Figure 2) (Schneider et al., 1997). TGF-
b signaling best illustrates a role for the Myc-Miz-1 interaction.
In the absence of TGF-b, Myc represses CDKN2B (p15INK4b)
by binding Miz-1 and displacing Miz-1 cofactors to silence
CDKN2B (Seoane et al., 2001). With TGF-b, MYC expression is
suppressed, and the Smad transcription factor translocates
and cooperates with Miz-1 to recruit NPM1 as a Miz-1 cofactor
to stimulate CDKN2B transcription and induce cell-cycle arrest
(Wanzel et al., 2008). Myc, on the other hand, activates many
ribosomal protein genes including Rpl23, which binds to and
retains NPM1 in the nucleolus, thereby inhibiting Miz-1 activity.
Myc itself is modulated by NPM1, which acts as a positive Myc
coactivator (Li et al., 2008).
Another critical mode for Myc-mediated gene repression is
through its ability to activate microRNAs (miRNAs) (Figure 3)
(Chang et al., 2008; O’Donnell et al., 2005). Specifically, the acti-
vation of the miR-17-92 cluster of miRNAs mediates a number of
biological activities of Myc, including the attenuation of E2F1
activity. Intriguingly, the miR-17-92 cluster also targets many
components of the TGF-b signaling pathway (Aguda et al.,
2008; Dews et al., 2010; Mestdagh et al., 2010; O’Donnell
et al., 2005). These observations indicate that Myc repression
of gene expression occurs through different modalities that
are linked to regulatory loops. Myc also represses many more
miRNAs, resulting in increased gene expression at the protein
level (Figure 3). It is almost certain that Myc would also directly24 Cell 149, March 30, 2012 ª2012 Elsevier Inc.activate long noncoding RNAs (lncRNAs) to mediate gene
repression, as implicated in studies of embryonic stem cells
(ESCs).
Transcription: Upstream and Downstream of Myc
The MYC protooncogene itself is under tight transcriptional
control as are the mRNA and Myc protein. In fact, MYC is
regulated not only by a whole host of transcription factors,
such as CNBP, FBP, and TCF (which is downstream of the
Wnt pathway), but also by non-B DNA structures including
single-stranded bubbles, G-quadruplexes, and Z-DNA (Levens,
2010). The FUSE (far upstream element) melts when bound by
FBP (FUSE-binding protein), which relieves torsional stresses
on DNA from ongoing transcription of MYC (He et al., 2000).
TCF is a transcription factor that plays a role in deregulated
MYC expression downstream of the WNT pathway, such as
with the loss of the tumor suppressor APC that results in consti-
tutive nuclear localization of the TCF cofactor b-catenin.
Genome-wide association studies further identified common
polymorphisms nearby MYC that are associated with multiple
cancers (Ahmadiyeh et al., 2010; Tuupanen et al., 2009; Wasser-
man et al., 2010). Such single-nucleotide polymorphisms
(SNPs) lie in enhancers that involve TCF binding and DNA
looping, which connects the enhancer to the MYC proximal
promoter (Pomerantz et al., 2009; Sotelo et al., 2010; Wright
et al., 2010). Recently, the BET domain containing transcriptional
regulator BRD4 was shown to bind to the MYC promoter region
and play a critical role inMYC expression in human cancer cells
such that a drug-like BET domain chemical inhibitor could inhibit
in vivo tumorigenesis (Delmore et al., 2011; Mertz et al., 2011).
Figure 4. Homeostatic and Proliferative Regulation of E Box-Driven
Genes
Myc-Max is shown bound to E box-driven genes, which could also be regu-
lated by other E box transcription factors, such as the carbohydrate response
element-binding protein (ChREBP), sterol response element-binding protein
(SREBP), nuclear respiratory factor 1 (NRF1), circadian transcription factor
Clock (and Bmal), and hypoxia-inducible factor (HIF). The non-Myc E box
transcription factors regulate genes involved in metabolism, which is main-
tained for cellular homeostasis when cells are not proliferating. Upon activation
ofMYC and elevated levels ofMyc,mass action favors the binding of Myc-Max
to E box genes to regulate metabolism and genes involved in ribosomal
biogenesis and cell mass accumulation. This model suggests that resting cells
express metabolic genes through ‘‘homeostatic’’ E box transcription factors,
which regulate a set of genes that overlaps with Myc target genes that are
expressed when cells are stimulated to grow and proliferate.The MYC mRNA, which is short lived, is affected by miRNAs
(let-7, miR-34, andmiR-145) resulting in translational modulation
(Cannell et al., 2010; Christoffersen et al., 2010; Kim et al., 2009;
Kress et al., 2011; Sachdeva et al., 2009). The Myc protein itself
is posttranslationally modified, ubiquitinated, and degraded,
with a half-life in the order of 15–20 min (Gregory and Hann,
2000; Gregory et al., 2003). Myc transcriptional activity is
regulated by phosphorylation at Ser62 followed by Thr58 and
subsequent proteasomal degradation after performing its func-
tion (Salghetti et al., 1999; Thomas and Tansey, 2011; Adhikary
et al., 2005; Popov et al., 2007, 2010). Mutations of Myc residues
Thr58 and Ser62, prevalently found in Burkitt lymphoma, are
associated with stabilized mutant proteins that could perturb
transgenic mammary tumorigenesis (Salghetti et al., 1999;
Thomas and Tansey, 2011; Wang et al., 2011b). The resulting
sustained levels of Myc contribute to tumorigenesis, which in
some instances may not require total elevated average levels
of Myc but rather depend on deregulated expression of Myc
throughout the cell cycle. How then does Myc transcriptional
activity contribute to tumorigenesis?
The canonical Myc E box 50-CACGTG-30 is among the most
frequently occurring DNA-binding motifs in the human genome
(Xie et al., 2005). This motif, however, could be bound by
different transcription factors such as ChREBP, SREBP, HIF-1,
NRF1, USF, TFE3, Clock, and Bmal (Figure 4). It stands to reason
that in nonproliferating cells, non-Myc E box transcription factors
regulate basal metabolism to maintain cellular structural and
functional integrity. When cells are stimulated to proliferate,
Myc levels rise, permitting Myc to occupy E box-driven genes
normally bound by other transcription factors and activatea program of biomass accumulation and enhanced cellular
bioenergetics. As such, which of the many E boxes are occupied
by Myc in proliferating cells, and does occupancy trigger
changes in transcription and mRNA levels of the target genes?
Genome-wide association of Myc protein to chromatin has
been documented by a number of approaches. Myc was docu-
mented by chromatin immunoprecipitation (ChIP) and quantita-
tive PCR to bind a selected panel of promoters (Fernandez
et al., 2003). A genome-wide study in Drosophila documented
key dMyc-bound target genes that are involved in many cellular
functions, consistent with studies performed in mammalian cells
(Orian et al., 2005); most notable among the Myc targets is the
cyclin-dependent kinase CDK4, which is also a key target
in mammals. Myc-binding sites were also mapped using a
promoter array containing 4,839 promoter sequences (Li et al.,
2003). This study suggests that Myc could be considered
a general transcriptional factor because promoters (15%) were
broadly bound by Myc. This study was corroborated by a sub-
sequent ChIP-chip tiled array study of human chromosomes
21 and 22, which documented widespread association of Myc
with chromatin (Cawley et al., 2004). Genome-wide Myc-binding
sites were mapped in a human B cell line with ChIP followed by
paired-ends tag sequencing (ChIP-PET) of the immunoprecipi-
tated DNA fragments (Zeller et al., 2006). This study estimated
that up to 6,000 genes are bound by Myc, and among the
3,000 genes deemed high-quality Myc-bound target genes,
only about 700 genes responded to Myc activation with alter-
ations in their mRNA levels. Most of these binding sites are found
in the proximal promoter, with significant portions found intra-
genically, and about 10% located in intergenic (>100 kb from
promoters) regions.
A subsequent study examines the role of Myc in transcription
and relief of RNA polymerase (Pol) II paused complexes (Rahl
et al., 2010). This study provides evidence suggesting that
recruitment of pTEFb by Myc stimulates pause release partly
by phosphorylation of RNA Pol II. This view is in contrast to the
previous perspective that transcription factors such as Myc
assemble cofactors, which in turn recruit TBP and RNA Pol II
for transcription initiation. In this regard, it is intriguing to note
that a significant proportion of Myc-binding sites occur in the
first introns of genes. Although the position of Myc-binding
sites and their effects on transcription pause release were not
specifically addressed, this work establishes a key role for Myc
in transcriptional elongation.
Genome-wide mapping of Myc-binding sites and associated
gene expression profiling established that Myc binding is insuffi-
cient to induce changes in mRNA levels of target genes. In fact,
many of the Myc-bound and -induced genes in the human B cell
model are associated with E2F DNA-binding motifs, suggesting
that Myc targets require additional factors for their expression
(Li et al., 2003; Zeller et al., 2006). An instructive study of Myc
among six other factors, including stem cell factors Sox2,
Oct4, and KLF4, and their binding sites in murine ESCs revealed
that genes whose expression is changed with stem cell differ-
entiation tend to be those that were bound by multiple transcrip-
tional factors (Kim et al., 2010). Hence, binding by a single
transcription factor is generally insufficient to activate a target
gene, unless it is bound by multiple transcriptional factors.Cell 149, March 30, 2012 ª2012 Elsevier Inc. 25
What then are the Myc target genes, and how do they contribute
to the biology of the cell?
Myc Target Genes, Stem Cells, and the Path to Cancer
Although low-throughput approaches to identify and charac-
terize Myc target genes were largely fruitful, a global perspective
of Myc function has only recently emerged from unbiased
studies of Myc targets. It is notable that early studies rely on
changes in mRNA levels in response to manipulation of Myc
levels to identify Myc target genes. Recently, the combination
of global chromatin immunoprecipitation and gene expression
profiling provides a better approach to defining Myc targets,
particularly if coupled with a genome-wide nuclear run-on assay
(Ji et al., 2011).
Through the use of an inducible Myc system coupled with
ChIP-seq and gene expression changes, a set of 300 Myc-
dependent serum response (MDSR) genes was identified in
fibroblasts (Perna et al., 2011). This set comprises about 6% of
Myc-bound targets, which encompass 22% of all promoters.
Intriguingly, theseMDSR genes are largely involved in nucleotide
metabolism, ribosome biogenesis, RNA processing, and DNA
replication. In this regard, Myc also regulates RNA Pol I- and
Pol III-mediated transcription in addition to its role in regulating
RNA Pol II genes (Felton-Edkins et al., 2003; Gomez-Roman
et al., 2003; Grandori et al., 2005; Kenneth et al., 2007). Thus,
the protein biosynthetic machinery is inherently linked to Myc
transcriptional activity, and the balance between rRNA syn-
thesis, ribosomal protein production, and the availability of
adequate bioenergetics is essential for normal cell growth.
Many direct Myc target genes encode ribosomal proteins, which
are directly involved in the ARF and p53 checkpoint, particularly
when ribosome biogenesis is perturbed.
A common 50 gene Myc core signature (MCS) was identified
among Myc target genes in four tumorigenic human cell lines
and in ESCs, and expression of the MCS correlates with MYC
gene expression among 8,129 microarray samples that include
312 cell and tissue types, attesting to its cell-type independence
(Ji et al., 2011). Functional annotation of the MCS reveals
enrichment of genes involved in ribosome biogenesis, under-
scoring Myc’s primordial function in biomass accumulation.
This notion is consistent with the observation that diminished
Drosophila dMyc function results in small cells and body size,
which phenocopies mutations affecting ribosomal protein genes
found in a large set of mutants termed Minutes (Johnston et al.,
1999). Furthermore, the link between Myc and ribosome biogen-
esis has been documented in specific cell types (Challagundla
et al., 2011; Chan et al., 2011; Greasley et al., 2000; Kim et al.,
2000; Schlosser et al., 2005; Schlosser et al., 2003) and in
Myc-driven tumorigenesis in vivo (Barna et al., 2008; Stumpf
and Ruggero, 2011). It is long known that cancer cells are
characterized by intense nucleolar hypertrophy; hence, a signa-
ture of cancer cells could now be linked mechanistically to Myc
function (van Riggelen et al., 2010b).
The role of Myc in reprogramming fibroblasts to pluripotency
and in stem cells emerges from a number of studies. One study
suggests that Myc drives an ESC-like program, without defining
the functional significance of this program (Wong et al., 2008).
The study by Kim et al. (2010), however, dissected the roles of26 Cell 149, March 30, 2012 ª2012 Elsevier Inc.stem cell factors (Sox2, Oct4) versus Myc through ChIP analysis
(Kim et al., 2010). In this case, stem cell factors regulate a distinct
core stem cell module of target genes, whereas Myc drives
a program common to ESCs and cancer cells but distinct from
the core stem cell targets. A third genetic module comprises
polycomb-related genes, which are involved in regulation of
cell differentiation. TheMycmodule is enriched in genes involved
in ribosome biogenesis, suggesting that the MCS does mark
a core function of Myc (Kim et al., 2010). It is notable, however,
that other studies implicate Myc in the regulation of chromatin
structure, which is reprogrammed in stem cells. Myc induces
Bmi-1 and EZH2, which are polycomb proteins, and perhaps
modulates the expression of lncRNAs that are involved in
polycomb-mediated gene silencing (Guney et al., 2006; Koh
et al., 2011b; Sander et al., 2008). Perhaps, these Myc functions
link Myc to the regulation of the polycomb module, the sup-
pression of senescence, terminal cell differentiation, and the
maintenance of pluripotency.
The role of Myc in tissue stem cells appears to depend on the
tissue type, andmultiple studies suggest thatMYC is required for
the commitment to terminal differentiation, which contrasts with
the role of MYC in pluripotency. MYC’s roles in tissue versus
pluripotent stem cells are expected to be different; however,
additional studies are required to provide a richer mechanistic
understanding. MYC is required for production of committed
hematopoietic progenitors such that loss ofMYC in mice results
in the expansion of hematopoietic stem cells (HSCs) and dimin-
ished progenitors with pancytopenia (Laurenti et al., 2008). On
the other hand, overexpression of MYC causes a decrease in
the HSC pool. Similarly, skin stem cells and pro-B cells require
Myc for differentiation tomature keratinocytes or B cells, respec-
tively (Frye et al., 2003; Gandarillas and Watt, 1997; Habib et al.,
2007; Iritani et al., 2002; Watt et al., 2008). Hence, transient
Myc-induced cell proliferation is coupled with differentiation
in multiple tissues in vivo. Although MYC is required for colonic
epithelial turnover, deletion of MYC in mouse hepatocytes
does not inhibit liver regeneration (Baena et al., 2005; Li et al.,
2006; Sansom et al., 2007; Wilkins and Sansom, 2008). It
remains unclear, however, whether N-Myc could play a role in
the absence of c-Myc in the liver. These studies collectively
indicate that Myc plays a critical role in tissue stem cell matura-
tion toward committed progenitors.
The study of the 50 gene MCS also allows for an analysis of
genes that are cell-type-specific Myc target genes (Ji et al.,
2011). In this regard, B cell-restricted genes such as BLMH
behave as a direct Myc target, and LIN28 behaves as a human
ESC-restricted Myc target, whereas FBL is an MCS gene
common to many cell types (Chang et al., 2009; Ji et al., 2011;
Koh et al., 2011a). These studies collectively suggest that
a key function of Myc is to drive biomass accumulation. Biomass
accumulation requires a commensurate level of bioenergetics
and building blocks, but genes involved in energy metabolism
are not found in the MCS. This observation suggests that
the bioenergetics of cells may depend on cell types. Among
normal cells there is a remarkable array of different metabolic
profiles, from highly aerobic (cardiac, brain) to adaptive anaer-
obic (skeletal muscle) cells. Hence, it could be the variable
uses of different energetic pathways among different cell
types that eliminate Myc target genes involved in metabolism
from the MCS.
Although the MCS defines a stringent cell-type-independent
set of Myc targets, other bona fide Myc targets have been firmly
identified in a number of systems. In fact, Myc directly regulates
genes involved in cell-cycle regulation, such as CDK4, which is
documented in mammalian and Drosophila cells as a Myc target
(Hermeking et al., 2000; Orian et al., 2003). In addition, Myc
regulates energy metabolism through its direct activation of
genes involved in glycolysis, glutamine metabolism, and mito-
chondrial biogenesis (Gao et al., 2009; Li et al., 2005; Osthus
et al., 2000; Shim et al., 1997; Wise et al., 2008). In this regard,
it seems thatMyc as amaster regulator affects a broad spectrum
of genes to coordinate energy metabolism with biomass
accumulation in preparation for DNA replication and cell division.
The cooperation of Myc with other transcription factors such as
E2F is necessary for the sequential expression of target genes as
the cell traverses through the cell cycle (Li et al., 2003; Pickering
et al., 2009; Zeller et al., 2006). Under hypoxia, normal Myc can
be suppressed by the hypoxia-inducible factor, HIF-1 (Gordan
et al., 2007, 2008; Zhang et al., 2007); however, deregulated
MYC expression appears to collaborate with HIF-1 to drive
glycolytic gene expression for cancer cell proliferation (Dang,
2007; Kim et al., 2007; Qing et al., 2010). The ability of Myc or
N-Myc to cooperate with HIF-1 could be highly relevant to the
ability of cancer cells to survive and proliferate under moderately
hypoxic conditions commonly found in the tumor microenviron-
ment. This perspective suggests that normal cell proliferation is
controlled by many of the same genes that are coordinated by
Myc in cancer cells. The question then is whether there are
distinctive features of normalMYC regulation of cell proliferation
versus those related to oncogenic (deregulated) MYC.
Metabolic and MYC Oncogene Addiction
In contrast to normal cells, in which the MYC protooncogene
is under stringent regulation downstream of many receptor
signaling pathways, including WNT, Hedgehog, Notch, TGF-b,
as well as many receptor tyrosine kinases, MYC activation in
cancer cells can result from constitutive activation of a pathway,
such as WNT in tumors with loss of APC, or through direct alter-
ations of the MYC gene, such as amplification or chromosomal
translocation. Furthermore, MYC amplification is documented
as a means to resist therapeutic inhibition of PI3K, indicating
that MYC is downstream of PI3K for tumorigenesis (Ilic et al.,
2011; Muellner et al., 2011). The deregulated expression of
MYC in cancers presumably causes a sustained increase in
Myc protein expression, perhaps throughout the cell cycle rather
than in a restricted manner. A threshold level for the pathological
expression of Myc has been documented in several systems,
supporting the concept that constitutive, elevated expression
of Myc contributes to tumorigenesis (Murphy et al., 2008;
Shachaf et al., 2008; Yustein et al., 2010). It is also reasonable
to hypothesize that constitutive Myc expression could cause
Myc to promiscuously activate E box-driven genes that would
be regulated by other E box transcription factors in the normal
nonproliferative cells.
It could be envisioned that nonproliferating cells express
certain E box genes for homeostatic purposes. For example,lipogenesis in nonproliferating liver or fat cells is mediated by
SREBP (Krycer et al., 2010). Mitochondrial biogenesis could be
stimulated in normal cells by NRF1, which binds E boxes and
is a target of Myc (Scarpulla, 2008). Certain E box-driven meta-
bolic genes are regulated in a circadian rhythm by Clock/Bmal,
whereas glycolytic and angiogenic genes can be activated by
HIF-1 in response to hypoxia (Asher and Schibler, 2011;
Semenza, 2007; Shchors et al., 2006). When Myc is elevated, it
could bind to the same targets that would be bound by other E
box transcription factors (Dang et al., 2008; Kim et al., 2007).
Hence, it is plausible that there is a switch in the regulation of
E box genes from homeostatic transcription to Myc transactiva-
tion, which orchestrates cell growth and proliferation. In this
regard, the ability of Myc to co-opt the functions of other E box
transcription factors would enable Myc to coordinate a growth
program along with angiogenesis (Baudino et al., 2002; Dews
et al., 2010; Knies-Bamforth et al., 2004). In the case of lipogenic
genes, their induction by Myc would be for lipid membrane
synthesis for a growing cell rather than for fat storage. Glycolytic
and mitochondrial genes would be induced by Myc to drive the
biosynthetic needs of proliferating cells. The metabolic gene
NAMPT, which is involved in NAD+ synthesis, is a circadian
gene responsive to Clock/Bmal in the liver (Ramsey et al.,
2009). The NAMPT gene is prominently bound by Myc and is
a direct Myc target gene (Menssen et al., 2012). Collectively,
these findings suggest that deregulated Myc commandeers
many of the E box genes to enable the cell to grow and then
divide, and in the case of neoplasia, Myc also drives angiogen-
esis (Figure 4).
Normal cells have feedback loops that negatively regulate
growth when deprived of nutrients or growth factors. Deprivation
of glucose from normal fibroblasts causes them towithdraw from
the cell cycle into the G1 phase of the cell cycle (Holley and
Kiernan, 1974). Perhaps this is due partly to the diminished levels
ofMyc under hypoxia or low-glucose conditions (Okuyama et al.,
2010). Because glucose is involved in multiple metabolic path-
ways including glycolysis (providing carbon skeletons for lipid
synthesis), the pentose phosphate pathway (ribose synthesis),
and glucosamine synthesis, its deprivation is expected to
profoundly affect normal cell proliferation. In contrast, glucose
withdrawal of Myc-overexpressing cells triggers apoptosis
(Shim et al., 1998). Likewise, glutamine withdrawal triggers
apoptosis of Myc-overexpressing cells (Yuneva et al., 2007). In
the recent study of normal primary activated murine T lympho-
cytes bearing floxed Myc alleles, it was found that the initial
phase of cell growth (cell size increase) was profoundly depen-
dent on Myc expression that drives target genes involved in
both glucose and glutamine metabolism. Loss of Myc was asso-
ciated with profoundly diminished expression of genes involved
in metabolism and the inability for normal primary T cells to grow
and proliferate (Wang et al., 2011a). It was also documented that
HIF-1, which regulates anaerobic glycolysis, was not required
for cell growth but required for T cell fate determination (Dang
et al., 2011; Shi et al., 2011). Given that Myc drives biomass
accumulation, the sensitivity of Myc-overexpressing cells to
nutrient deprivation could reflect their deregulated growth,
which renders them dependent on and addicted to continual
bioenergetic sources, such as glucose and glutamine.Cell 149, March 30, 2012 ª2012 Elsevier Inc. 27
Although nutrient dependency characterizes a feature of Myc-
transformed cells, it has been recognized in transgenic models
that Myc-induced tumors are also addicted to Myc, such that
conditional silencing of ectopic Myc expression causes tumor
regression in a number of different tumor models. The collapse
of the tumor microenvironment and neovasculature could
account for the oncogene addiction (Giuriato et al., 2006; Sodir
et al., 2011). In these cases, the time-dependent changes in
the Myc-induced genetic program when Myc is turned off may
cause an asynchrony between bioenergetics demands and fuel
sources. Inactivation of Myc can also restore the normal TGF-b
regulatory circuitry, such that loss of Myc would reactivate
SMAD-Miz-1-mediated activation of p21 downstream of
TGF-b, culminating in cell-cycle arrest and senescence (van
Riggelen et al., 2010a). Finally, immune cells are critical com-
ponents of the tumor microenvironment, and in this regard,
they affect Myc’s ability to regulate angiogenesis and senes-
cence (Rakhra et al., 2010).
Conceptually, it appears that regulation of Myc expression
in normal cells is orchestrated in a fashion that withdrawal of
growth signals is followed by an orderly recession of gene
expression programs such that there is a balance between fuel
needs and fuel supply and utilization by the normal cell. In
Myc-overexpressing transformed cells, deregulated Myc
presumably alters expression and the balance among the target
genes such that Myc withdrawal is followed by an asynchronous
recession of the target gene network, resulting in an imbalance
between nutrient supply and demand. In some cases, a brief
suppression ofMYC is sufficient to reverse in vivo tumorigenesis
(Jain et al., 2002), but not in other cases (Boxer et al., 2004;
Jonkers and Berns, 2004; Shachaf et al., 2004), suggesting
that tissue specificity and either other mutagenic events or
epigenetic alterations affect the reversibility of tumorigenesis
upon Myc suppression. Suppression of MYC could trigger
senescence or cause an imbalance between apoptotic and
antiapoptotic gene expression and could also tip the scale
toward cell death with Myc withdrawal (Felsher, 2010; Wu
et al., 2007; Zhuang et al., 2008). It is reasonable to hypothesize
that the imbalance between energy demand and supply
upon Myc withdrawal could also play a role in Myc oncogene
addiction.
Metastasis and Genome Instability Induced by Myc
Cancer cells are not just characterized by the propensity
to proliferate with disregard to extracellular cues but also
underscored by increased genomic instability, changes in
morphology and function such as epithelial-mesenchymal
transition (EMT), and an increased ability to metastasize. Given
that Myc can repress genes involved in cell-cell and cell-
substratum contacts and that these processes would be
diminished as normal cells detach from neighboring cells to
undergo mitosis, it should not be surprising that overexpressed
Myc would also elicit these phenotypes (Dang et al., 2006).
Myc has been linked to EMT and metastasis via its regulation
of miRNA miR-9, which targets E-cadherin, as well as its ability
to transactivate Bmi-1 which is linked to EMT (Ma et al., 2010;
Song et al., 2009). Whether Myc plays a similar parallel role in
nonpathologic conditions is not clear.28 Cell 149, March 30, 2012 ª2012 Elsevier Inc.Overexpression of Myc in a number of cell systems in vitro has
been linked to increased genomic instability (Felsher andBishop,
1999b; Karlsson et al., 2003; Neiman et al., 2006; Prochownik,
2008; Ray et al., 2006). Myc induction of reactive oxygen species
(ROS), presumably through its induction of mitochondrial
biogenesis and increased metabolism, has been implicated in
genomic instability (Egler et al., 2005; Gao et al., 2007; Vafa
et al., 2002; Zhang et al., 2007). Here it could be envisioned
that normal cells with normal regulated Myc would have the
appropriate compensatory mechanisms to detoxify free oxygen
radicals, whereas highly active Myc would induce a sustained
ROS insult on the genome, causing instability (Egler et al.,
2005; Graves et al., 2009; Wonsey et al., 2002). Whether ROS
is central to Myc-induced genomic instability is unclear, particu-
larly given that Myc could directly affect telomere function and
increase genome instability (Louis et al., 2005). Intriguingly, in
a transgenic lymphoma model with inducible Myc, many of the
tumors display remarkable chromosomal rearrangements,
suggesting that Myc affects chromosomal stability, but the
molecular details remained undefined (Karlsson et al., 2003).
Myc is, however, known to regulate a number of components
of the mitotic checkpoint; whether deregulated expression of
these components contributes to chromosomal instability
remains to be studied (Li and Dang, 1999; Menssen et al., 2007).
Therapeutic Opportunities
MYC certainly seems to be at the crossroads of many important
biological pathways and processes involved in neoplastic cell
growth and proliferation. MYC is documented to be involved
broadly in many cancers, in which its expression is estimated
to be elevated or deregulated in up to 70% of human cancers.
High levels of MYC expression have been linked to aggressive
human prostate cancer and triple-negative breast cancer (Gurel
et al., 2008; Palaskas et al., 2011). Experimental models of
Myc-mediated tumorigenesis suggest that established tumors
are addicted to Myc and that deregulated expression of Myc
results in an addiction not only to Myc but also to nutrients.
These Myc-induced changes provide a unique opportunity for
new therapeutic strategies. Notwithstanding the fact that normal
proliferating cells (stem cell compartments and immune cells)
also useMYC for renewal, many studies have focused on target-
ing Myc for cancer therapeutics. Strategies have emerged to
inhibit MYC expression, to interrupt Myc-Max dimerization, to
inhibit Myc-Max DNA binding, and to interfere with key Myc
target genes.
Although there has been significant attention to the G-quadru-
plex regulatory sequence in theMYC promoter as a therapeutic
target, current available compounds that lock the G-quadruplex
into an ‘‘off’’ mode are not yet shown to be effective in the
preclinical setting (Brown et al., 2011; Dai et al., 2011). Intrigu-
ingly, the BET bromain domain regulatory proteins recently
emerged as potent regulators of MYC expression in different
tumor types. In particular, inhibition of BET with a drug-like
molecule in multiple myeloma, a malignant plasma cell tumor,
resulted in a remarkable diminution of MYC expression and
associated cell death. In this regard, it is also notable that
a number of Burkitt lymphoma cell lines withMYC translocations
are also susceptible to growth inhibition by BET inhibitors.
Inhibition of the BET BRD4 protein, thus, proves effective in an
in vivo preclinical mode, suggesting that targeting MYC expres-
sion is feasible in selected cancers (Delmore et al., 2011; Mertz
et al., 2011).
The strategy directed toward interrupting Myc-Max dimeriza-
tion has been forged by several groups (Clausen et al., 2010;
Follis et al., 2008, 2009; Hammoudeh et al., 2009; Huang et al.,
2006; Mustata et al., 2009; Park et al., 2004; Prochownik and
Vogt, 2010). Although proof-of-concept has been documented
with inhibitors effective in the micromolar concentration range
in vitro, evidence for in vivo effectiveness is still lacking.
Nothwithstanding this limitation, the proof-of-concept provided
to date suggests that this avenue could be fruitful particularly
when new chemistry is applied, such as click-chemistry that
bridges two moderate inhibitors against neighboring protein
domains of the target to form a more effective inhibitor. Another
approach is to consider the unstructured transcriptional regula-
tory domain and the DNA-binding domain (until it makes contact
with DNA) as potential targets for small molecules that would
nucleate polypeptide folding and lock the domain in a nonfunc-
tional conformation.
Other strategies have focused on targeting Myc target genes.
For example, Myc repression of miR-26a in a Myc-induced liver
model of liver cancer has been exploited by treating tumor-
bearing animals with adenovirus-associated viral expression of
miR-26a (Kota et al., 2009). This strategy results in a remarkable
response in this liver cancer model, suggesting that interfering
with Myc-regulated miRNAs could be therapeutically feasible
(Frenzel et al., 2010; Love´n et al., 2010). Myc target genes
such as ornithine decarboxylase (ODC), lactate dehydrogenase
A (LDHA), and glutaminase (GLS) have also been targeted by
shRNAs or drug-like small molecules in vivo (Figure 3) (Fantin
et al., 2006; Le et al., 2010, 2012; Seltzer et al., 2010; Seth
et al., 2011; Wang et al., 2010; Xie et al., 2009). These scenarios
rely on the necessity of these target genes for the full transform-
ing ability of Myc. It is expected, even with promising preclinical
responses to targeting Myc or its target genes, that tumor types
and context will add to the complexity and heterogeneity of
response to any one strategy. In fact, the avidity of the triple-
negative breast cancer subtype for glucose as determined by
PET scanning using radiolabeled 18F-deoxyglucose has been
linked to a MYC gene expression signature, which contains
components of glucose fermentation or glycolysis (Palaskas
et al., 2011). Thus, targeting metabolism could be strategically
aimed at triple-negative breast cancers rather than the estrogen
receptor-positive tumors.
Recent screens for synthetic lethality inMyc-transformed cells
will also likely provide new therapeutic opportunities such as
targeting the death receptor pathway or the use of inhibitors
against the aurora- or cyclin-dependent kinases (den Hollander
et al., 2010; Yang et al., 2010). A recent synthetic dosage lethality
screen uncovered sumoylation of Myc as an essential element
for tumor cell growth (Kessler et al., 2012). Further, Myc-induced
replicative stress renders transgenic murine lymphomas sensi-
tive to Chk1 inhibitors (Murga et al., 2011). Although synthetic
lethality screens are unbiased with respect to the targets, the
screens are inherently limited by the choice of tumor cell type.
Here, cellular and tissue type context may also affect responsesand the spectrum of synthetically lethal targets. In this regard,
new therapies targeting Myc, its target genes, or synthetically
lethal targets may best be applied in the future together with
molecular profiling of cancers for clinical stratification and selec-
tion of combination therapies.
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